GlassScriptPhysician profile
Robert F Tzeng
NPI 1578665014
$11,791.22
in general payments reported to CMS, 2019-2025
41 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,059 · 2020: $2,315 · 2021: $2,315 · 2022: $1,028 · 2023: $1,295 · 2024: $1,399 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,009 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,008.96 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,855.31 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amarin Pharma, INC. | $970.71 | 2019-2022 | |
| Amgen INC. | $968.50 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $957.37 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $857.23 | 2019-2025 | Jardiance |
| Abbvie INC. | $644.15 | 2019-2024 | Linzess, Creon |
| Lilly USA, LLC | $624.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $474.44 | 2019-2022 | |
| Astellas Pharma US INC | $453.94 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $415.86 | 2019-2025 | Verquvo, Lagevrio |
| Radius Health, INC. | $404.81 | 2019-2025 | Tymlos |
| Kowa Pharmaceuticals America, INC. | $399.56 | 2019-2025 | Livalo, Zoryve, Seglentis |
| Gilead Sciences, INC. | $250.00 | 2024-2025 | Vemlidy |
| Phathom Pharmaceuticals, INC. | $206.87 | 2024 | Voquezna |
| Vivus LLC | $202.86 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tzeng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.